[{"id":"5035de87-13e9-4f08-bf94-89d31bbe7a39","acronym":"","url":"https://clinicaltrials.gov/study/NCT05660083","created_at":"2022-12-21T14:58:46.993Z","updated_at":"2025-02-25T15:54:44.104Z","phase":"Phase 2","brief_title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","source_id_and_acronym":"NCT05660083","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • albumin-bound paclitaxel • tilarginine (L-NMMA)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/12/2023","start_date":" 01/12/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/02/2028","study_completion_date":" 12/02/2028","last_update_posted":"2024-02-07"},{"id":"807674cf-1bc0-43eb-bae4-f7928e8936a0","acronym":"Pro00011685","url":"https://clinicaltrials.gov/study/NCT02834403","created_at":"2021-01-18T13:54:35.762Z","updated_at":"2024-07-02T16:35:26.085Z","phase":"Phase 1/2","brief_title":"L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients","source_id_and_acronym":"NCT02834403 - Pro00011685","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" HER-2 • ER • PIK3CA • PGR","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation • ER negative • PGR negative","tags":["HER-2 • ER • PIK3CA • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Neulasta (pegfilgrastim) • tilarginine (L-NMMA) • aspirin"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2023-12-15"},{"id":"253c5280-5fd4-4dd7-bc31-3d6c20fdc271","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236935","created_at":"2021-01-18T15:59:44.648Z","updated_at":"2024-07-02T16:35:48.962Z","phase":"Phase 1","brief_title":"Phase Ib of L-NMMA and Pembrolizumab","source_id_and_acronym":"NCT03236935","lead_sponsor":"The Methodist Hospital Research Institute","biomarkers":" PD-L1 • BRAF • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation","tags":["PD-L1 • BRAF • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tilarginine (L-NMMA)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/03/2018","start_date":" 08/03/2018","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 12/28/2023","study_completion_date":" 12/28/2023","last_update_posted":"2023-05-04"}]